Needham Reiterates Buy Rating on Lyell Immunopharma, Inc. (LYEL)

Market Context

Lyell Immunopharma, Inc. operates in the Healthcare sector. The stock currently trades at $10.77 with a market capitalization of $708.0M. The stock has declined 34.2% over the past 52 weeks.

Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Lyell Immunopharma, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Lyell Immunopharma, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 03, 2026	Needham	Buy	N/A
Sep 11, 2026	Needham	Buy	N/A
Aug 06, 2026	Stifel	Buy	N/A
Jul 22, 2026	B. Riley Securities	Buy	N/A
Jun 15, 2026	Citizens	Market Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View LYEL Stock Page